Leadership

Jingjun “Jim” Huang, Ph.D. - CEO & CSO

Dr. Huang founded Ascendia after a career in pharmaceutical R&D and management at Pfizer, Baxter, AstraZeneca, and most recently Roche. He has led the formulation development efforts for the successful transition of several oral and parenteral dosage forms from discovery through formulation, manufacturing, technical transfer and ultimately commercialization. Dr. Huang holds a Ph.D. in Pharmaceutics from the University of the Sciences in Philadelphia (formerly Philadelphia College of Pharmacy and Sciences) where he worked with Joseph B. Schwartz.

Dr. Huang’s research interests are centered on improvement of solubility and dissolution for, and controlled delivery of, poorly water soluble drugs through nano-emulsion, nano-particle and amorphous solid dispersion technologies. His publications include studies on drug solubilization and controlled delivery in polymeric solid dispersion systems, amorphous drug delivery systems, controlled release, modeling and simulation, thermal and spectroscopic characterization of amorphous molecular dispersions, drug-polymer interactions and its significance on physical stability of amorphous drug, and micro/nano particulates for use in parenteral dosage forms. He has been a reviewer for the Journal of Pharmaceutical Sciences, International Journal of Pharmaceutics, Journal of Controlled Release, Drug Development and Industrial Pharmacy, PDA Journal of Pharmaceutical Science and Technology, Molecular Pharmaceutics, and Pharmaceutical Research. Currently, he is a member of the American Association of Pharmaceutical Scientists (AAPS) and the American Chemical Society (ACS).
 

 

Robert Bloder - Chief Business Officer, Board Advisor

Mr. Robert Bloder joined Ascendia after a thirty-year successful career in pharmaceuticals business development and commercialization from Aptex, where he was most recently Vice President of Global Business Development. Mr. Bloder is award-winning pharmaceutical executive with an accomplished global track-record in big and specialty pharma, as well as, generics and CDMO with drug delivery.

Mr. Robert J. Bloder was the Vice President of Global Business Development for Apotex, the 7th largest specialty pharmaceutical company with over 10,000 employees and sales in excess of $2 Billion. Prior to joining Apotex, Mr Bloder was a Board Member & Vice President of Business Development at Aveva Drug Delivery Systems (sold to Apotex); Mr Bloder co-founded the specialty pharmaceutical company, ESP Pharma and served as the Vice President of Market Development, contributing to successful launch of CARDENE IV (nicardipine hydrochloride) premixed injection for intravenous use. Prior to co-founding ESP Pharma, Mr. Bloder was the Director of Strategic Partnership Development for Pfizer (formerly Parke-Davis), where he co-developed and managed day to day operations of an internal business accelerator that focused on the company’s largest, revenue-generating products like Lipitor & Neurontin. During his sales and marketing tenure at Parke-Davis, Mr Bloder launched several blockbuster and “first in class” products that fulfilled unmet market needs. Mr Bloder holds a Bachelor’s degree of Science from Bethany College.





Donald Pennino, Ph.D.-Vice President, Quality


Dr. Pennino has over 45 years experience in the pharmaceutical, biotechnology, and medical device industries. He  holds a Ph.D. in Physical Chemistry from Stevens Institute of Technology in Hoboken, NJ. He has managed, designed and built many analytical, quality control, and aseptic operation controlled areas over his career. He has extensive validation expertise, as well as practical drug development, helping to bring to market many products by companies such as Novartis, Warner-Lambert, Schering-Plough, Pfizer, Stryker BioTech, CR Bard, Chiron and Celator. He used to work on DoD projects to develop prophylactic vaccines as defense to potential bioterrorism threats in the US. He also had served as an expert to industry providing regulatory solutions in the area of quality, remediation and compliance.
Sign Up Now For Updates